BRAF G464V

CI-VAR-00001740Explore in graph →NP_004324.2:p.Gly464ValNM_004333.4:c.1391G>TClinVar 40364 CIViC 1106 rs121913348

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
BRAF G464V	Sorafenib	Predictive	D	Supports Sensitivity Response	1	submitted	EID2811 In an attempt to block both MAPK and PI3K/Akt pathways, two signaling inhibitors (sorafenib, a BRAF kinase inhibitor, and ceramide, an agent that dephosphorylates Akt) were used in cell culture and mo… (full text at CIViC) PMID 18519791 · Tran et al., 2008 · Open in CIViC	civic
Malignant Neoplasm1
BRAF G464V	Vemurafenib	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5964 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
40364	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	RASopathy; Non-small cell lung carcinoma; Noonan syndrome and Noonan-related syndrome; Cardiofaciocutaneous syndrome 1; Ovarian Sertoli-Leydig cell tumor	germline/somatic	8	Jul 16, 2023	clinvar